North America (NAFTA) Pharmaceuticals Market Summary, Competitive Analysis and Forecast, 2018-2027
North America (NAFTA) Pharmaceuticals Market Summary, Competitive Analysis and Forecast, 2018-2027
Summary
The NAFTA Pharmaceuticals industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value 2018-22, and forecast to 2027). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
Key Highlights
Summary
The NAFTA Pharmaceuticals industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value 2018-22, and forecast to 2027). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
Key Highlights
- The North American Free Trade Agreement (NAFTA) is a trade agreement between the countries in North America: the US, Canada and Mexico. The pharmaceuticals industry within the NAFTA countries had a total market value of $459.6 billion in 2022.The Mexico was the fastest growing country, with a CAGR of 8% over the 2018-22 period.
- Within the pharmaceuticals industry, the US is the leading country among the NAFTA bloc, with market revenues of $408.0 billion in 2022. This was followed by Canada and Mexico, with a value of $26.1 and $25.5 billion, respectively.
- The US is expected to lead the pharmaceuticals industry in the NAFTA bloc, with a value of $463.0 billion in 2027, followed by Mexico and Canada with expected values of $37.8 and $27.3 billion, respectively.
- Save time carrying out entry-level research by identifying the size, growth, and leading players in the NAFTA pharmaceuticals market
- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the NAFTA pharmaceuticals market
- Leading company profiles reveal details of key pharmaceuticals market players’ NAFTA operations and financial performance
- Add weight to presentations and pitches by understanding the future growth prospects of the NAFTA pharmaceuticals market with five year forecasts
- Compares data from the US, Canada and Mexico, alongside individual chapters on each country
- What was the size of the NAFTA pharmaceuticals market by value in 2022?
- What will be the size of the NAFTA pharmaceuticals market in 2027?
- What factors are affecting the strength of competition in the NAFTA pharmaceuticals market?
- How has the market performed over the last five years?
- Who are the top competitors in the NAFTA pharmaceuticals market?
1 INTRODUCTION
1.1. What is this report about?
1.2. Who is the target reader?
1.3. How to use this report
1.4. Definitions
2 NAFTA PHARMACEUTICALS
2.1. Industry Outlook
3 PHARMACEUTICALS IN CANADA
3.1. Market Overview
3.2. Market Data
3.3. Market Segmentation
3.4. Market outlook
3.5. Five forces analysis
4 MACROECONOMIC INDICATORS
4.1. Country data
5 PHARMACEUTICALS IN MEXICO
5.1. Market Overview
5.2. Market Data
5.3. Market Segmentation
5.4. Market outlook
5.5. Five forces analysis
6 MACROECONOMIC INDICATORS
6.1. Country data
7 PHARMACEUTICALS IN THE UNITED STATES
7.1. Market Overview
7.2. Market Data
7.3. Market Segmentation
7.4. Market outlook
7.5. Five forces analysis
8 MACROECONOMIC INDICATORS
8.1. Country data
9 COMPANY PROFILES
9.1. Johnson & Johnson
9.2. Apotex, Inc.
9.3. Sanofi SA
9.4. Genomma Lab Internacional SAB de CV
9.5. Merck & Co., Inc.
9.6. Pfizer Inc.
9.7. AstraZeneca PLC
10 APPENDIX
10.1. Methodology
10.2. About MarketLine
1.1. What is this report about?
1.2. Who is the target reader?
1.3. How to use this report
1.4. Definitions
2 NAFTA PHARMACEUTICALS
2.1. Industry Outlook
3 PHARMACEUTICALS IN CANADA
3.1. Market Overview
3.2. Market Data
3.3. Market Segmentation
3.4. Market outlook
3.5. Five forces analysis
4 MACROECONOMIC INDICATORS
4.1. Country data
5 PHARMACEUTICALS IN MEXICO
5.1. Market Overview
5.2. Market Data
5.3. Market Segmentation
5.4. Market outlook
5.5. Five forces analysis
6 MACROECONOMIC INDICATORS
6.1. Country data
7 PHARMACEUTICALS IN THE UNITED STATES
7.1. Market Overview
7.2. Market Data
7.3. Market Segmentation
7.4. Market outlook
7.5. Five forces analysis
8 MACROECONOMIC INDICATORS
8.1. Country data
9 COMPANY PROFILES
9.1. Johnson & Johnson
9.2. Apotex, Inc.
9.3. Sanofi SA
9.4. Genomma Lab Internacional SAB de CV
9.5. Merck & Co., Inc.
9.6. Pfizer Inc.
9.7. AstraZeneca PLC
10 APPENDIX
10.1. Methodology
10.2. About MarketLine
LIST OF TABLES
Table 1: NAFTA countries pharmaceuticals industry, revenue ($bn), 2018-27
Table 2: NAFTA countries pharmaceuticals industry, revenue ($bn), 2018-22
Table 3: NAFTA countries pharmaceuticals industry forecast, revenue ($bn), 2022-27
Table 4: Canada pharmaceuticals market value: $ billion, 2017-22
Table 5: Canada pharmaceuticals market geography segmentation: $ billion, 2022
Table 6: Canada pharmaceuticals market value forecast: $ billion, 2022–27
Table 7: Canada size of population (million), 2018–22
Table 8: Canada gdp (constant 2005 prices, $ billion), 2018–22
Table 9: Canada gdp (current prices, $ billion), 2018–22
Table 10: Canada inflation, 2018–22
Table 11: Canada consumer price index (absolute), 2018–22
Table 12: Canada exchange rate, 2018–22
Table 13: Mexico pharmaceuticals market value: $ billion, 2017-22
Table 14: Mexico pharmaceuticals market geography segmentation: $ billion, 2022
Table 15: Mexico pharmaceuticals market value forecast: $ billion, 2022–27
Table 16: Mexico size of population (million), 2018–22
Table 17: Mexico gdp (constant 2005 prices, $ billion), 2018–22
Table 18: Mexico gdp (current prices, $ billion), 2018–22
Table 19: Mexico inflation, 2018–22
Table 20: Mexico consumer price index (absolute), 2018–22
Table 21: Mexico exchange rate, 2018–22
Table 22: United States pharmaceuticals market value: $ billion, 2017-22
Table 23: United States pharmaceuticals market geography segmentation: $ billion, 2022
Table 24: United States pharmaceuticals market value forecast: $ billion, 2022–27
Table 25: United States size of population (million), 2018–22
Table 26: United States gdp (constant 2005 prices, $ billion), 2018–22
Table 27: United States gdp (current prices, $ billion), 2018–22
Table 28: United States inflation, 2018–22
Table 29: United States consumer price index (absolute), 2018–22
Table 30: United States exchange rate, 2018–22
Table 31: Johnson & Johnson: key facts
Table 32: Johnson & Johnson: Annual Financial Ratios
Table 33: Johnson & Johnson: Key Employees
Table 34: Johnson & Johnson: Key Employees Continued
Table 35: Apotex, Inc.: key facts
Table 36: Apotex, Inc.: Key Employees
Table 37: Sanofi SA: key facts
Table 38: Sanofi SA: Annual Financial Ratios
Table 39: Sanofi SA: Key Employees
Table 40: Sanofi SA: Key Employees Continued
Table 41: Genomma Lab Internacional SAB de CV: key facts
Table 42: Genomma Lab Internacional SAB de CV: Annual Financial Ratios
Table 43: Genomma Lab Internacional SAB de CV: Key Employees
Table 44: Merck & Co., Inc.: key facts
Table 45: Merck & Co., Inc.: Annual Financial Ratios
Table 46: Merck & Co., Inc.: Key Employees
Table 47: Merck & Co., Inc.: Key Employees Continued
Table 48: Pfizer Inc.: key facts
Table 49: Pfizer Inc.: Annual Financial Ratios
Table 50: Pfizer Inc.: Key Employees
Table 51: Pfizer Inc.: Key Employees Continued
Table 52: AstraZeneca PLC: key facts
Table 53: AstraZeneca PLC: Annual Financial Ratios
Table 54: AstraZeneca PLC: Key Employees
Table 55: AstraZeneca PLC: Key Employees Continued
Table 1: NAFTA countries pharmaceuticals industry, revenue ($bn), 2018-27
Table 2: NAFTA countries pharmaceuticals industry, revenue ($bn), 2018-22
Table 3: NAFTA countries pharmaceuticals industry forecast, revenue ($bn), 2022-27
Table 4: Canada pharmaceuticals market value: $ billion, 2017-22
Table 5: Canada pharmaceuticals market geography segmentation: $ billion, 2022
Table 6: Canada pharmaceuticals market value forecast: $ billion, 2022–27
Table 7: Canada size of population (million), 2018–22
Table 8: Canada gdp (constant 2005 prices, $ billion), 2018–22
Table 9: Canada gdp (current prices, $ billion), 2018–22
Table 10: Canada inflation, 2018–22
Table 11: Canada consumer price index (absolute), 2018–22
Table 12: Canada exchange rate, 2018–22
Table 13: Mexico pharmaceuticals market value: $ billion, 2017-22
Table 14: Mexico pharmaceuticals market geography segmentation: $ billion, 2022
Table 15: Mexico pharmaceuticals market value forecast: $ billion, 2022–27
Table 16: Mexico size of population (million), 2018–22
Table 17: Mexico gdp (constant 2005 prices, $ billion), 2018–22
Table 18: Mexico gdp (current prices, $ billion), 2018–22
Table 19: Mexico inflation, 2018–22
Table 20: Mexico consumer price index (absolute), 2018–22
Table 21: Mexico exchange rate, 2018–22
Table 22: United States pharmaceuticals market value: $ billion, 2017-22
Table 23: United States pharmaceuticals market geography segmentation: $ billion, 2022
Table 24: United States pharmaceuticals market value forecast: $ billion, 2022–27
Table 25: United States size of population (million), 2018–22
Table 26: United States gdp (constant 2005 prices, $ billion), 2018–22
Table 27: United States gdp (current prices, $ billion), 2018–22
Table 28: United States inflation, 2018–22
Table 29: United States consumer price index (absolute), 2018–22
Table 30: United States exchange rate, 2018–22
Table 31: Johnson & Johnson: key facts
Table 32: Johnson & Johnson: Annual Financial Ratios
Table 33: Johnson & Johnson: Key Employees
Table 34: Johnson & Johnson: Key Employees Continued
Table 35: Apotex, Inc.: key facts
Table 36: Apotex, Inc.: Key Employees
Table 37: Sanofi SA: key facts
Table 38: Sanofi SA: Annual Financial Ratios
Table 39: Sanofi SA: Key Employees
Table 40: Sanofi SA: Key Employees Continued
Table 41: Genomma Lab Internacional SAB de CV: key facts
Table 42: Genomma Lab Internacional SAB de CV: Annual Financial Ratios
Table 43: Genomma Lab Internacional SAB de CV: Key Employees
Table 44: Merck & Co., Inc.: key facts
Table 45: Merck & Co., Inc.: Annual Financial Ratios
Table 46: Merck & Co., Inc.: Key Employees
Table 47: Merck & Co., Inc.: Key Employees Continued
Table 48: Pfizer Inc.: key facts
Table 49: Pfizer Inc.: Annual Financial Ratios
Table 50: Pfizer Inc.: Key Employees
Table 51: Pfizer Inc.: Key Employees Continued
Table 52: AstraZeneca PLC: key facts
Table 53: AstraZeneca PLC: Annual Financial Ratios
Table 54: AstraZeneca PLC: Key Employees
Table 55: AstraZeneca PLC: Key Employees Continued
LIST OF FIGURES
Figure 1: NAFTA countries pharmaceuticals industry, revenue ($bn), 2018-27
Figure 2: NAFTA countries pharmaceuticals industry, revenue ($bn), 2018-22
Figure 3: NAFTA countries pharmaceuticals industry forecast, revenue ($bn), 2022-27
Figure 4: Canada pharmaceuticals market value: $ billion, 2017-22
Figure 5: Canada pharmaceuticals market geography segmentation: % share, by value, 2022
Figure 6: Canada pharmaceuticals market value forecast: $ billion, 2022–27
Figure 7: Forces driving competition in the pharmaceuticals market in Canada, 2022
Figure 8: Drivers of buyer power in the pharmaceuticals market in Canada, 2022
Figure 9: Drivers of supplier power in the pharmaceuticals market in Canada, 2022
Figure 10: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Canada, 2022
Figure 11: Factors influencing the threat of substitutes in the pharmaceuticals market in Canada, 2022
Figure 12: Drivers of degree of rivalry in the pharmaceuticals market in Canada, 2022
Figure 13: Mexico pharmaceuticals market value: $ billion, 2017-22
Figure 14: Mexico pharmaceuticals market geography segmentation: % share, by value, 2022
Figure 15: Mexico pharmaceuticals market value forecast: $ billion, 2022–27
Figure 16: Forces driving competition in the pharmaceuticals market in Mexico, 2022
Figure 17: Drivers of buyer power in the pharmaceuticals market in Mexico, 2022
Figure 18: Drivers of supplier power in the pharmaceuticals market in Mexico, 2022
Figure 19: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Mexico, 2022
Figure 20: Factors influencing the threat of substitutes in the pharmaceuticals market in Mexico, 2022
Figure 21: Drivers of degree of rivalry in the pharmaceuticals market in Mexico, 2022
Figure 22: United States pharmaceuticals market value: $ billion, 2017-22
Figure 23: United States pharmaceuticals market geography segmentation: % share, by value, 2022
Figure 24: United States pharmaceuticals market value forecast: $ billion, 2022–27
Figure 25: Forces driving competition in the pharmaceuticals market in the United States, 2022
Figure 26: Drivers of buyer power in the pharmaceuticals market in the United States, 2022
Figure 27: Drivers of supplier power in the pharmaceuticals market in the United States, 2022
Figure 28: Factors influencing the likelihood of new entrants in the pharmaceuticals market in the United States, 2022
Figure 29: Factors influencing the threat of substitutes in the pharmaceuticals market in the United States, 2022
Figure 30: Drivers of degree of rivalry in the pharmaceuticals market in the United States, 2022
Figure 1: NAFTA countries pharmaceuticals industry, revenue ($bn), 2018-27
Figure 2: NAFTA countries pharmaceuticals industry, revenue ($bn), 2018-22
Figure 3: NAFTA countries pharmaceuticals industry forecast, revenue ($bn), 2022-27
Figure 4: Canada pharmaceuticals market value: $ billion, 2017-22
Figure 5: Canada pharmaceuticals market geography segmentation: % share, by value, 2022
Figure 6: Canada pharmaceuticals market value forecast: $ billion, 2022–27
Figure 7: Forces driving competition in the pharmaceuticals market in Canada, 2022
Figure 8: Drivers of buyer power in the pharmaceuticals market in Canada, 2022
Figure 9: Drivers of supplier power in the pharmaceuticals market in Canada, 2022
Figure 10: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Canada, 2022
Figure 11: Factors influencing the threat of substitutes in the pharmaceuticals market in Canada, 2022
Figure 12: Drivers of degree of rivalry in the pharmaceuticals market in Canada, 2022
Figure 13: Mexico pharmaceuticals market value: $ billion, 2017-22
Figure 14: Mexico pharmaceuticals market geography segmentation: % share, by value, 2022
Figure 15: Mexico pharmaceuticals market value forecast: $ billion, 2022–27
Figure 16: Forces driving competition in the pharmaceuticals market in Mexico, 2022
Figure 17: Drivers of buyer power in the pharmaceuticals market in Mexico, 2022
Figure 18: Drivers of supplier power in the pharmaceuticals market in Mexico, 2022
Figure 19: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Mexico, 2022
Figure 20: Factors influencing the threat of substitutes in the pharmaceuticals market in Mexico, 2022
Figure 21: Drivers of degree of rivalry in the pharmaceuticals market in Mexico, 2022
Figure 22: United States pharmaceuticals market value: $ billion, 2017-22
Figure 23: United States pharmaceuticals market geography segmentation: % share, by value, 2022
Figure 24: United States pharmaceuticals market value forecast: $ billion, 2022–27
Figure 25: Forces driving competition in the pharmaceuticals market in the United States, 2022
Figure 26: Drivers of buyer power in the pharmaceuticals market in the United States, 2022
Figure 27: Drivers of supplier power in the pharmaceuticals market in the United States, 2022
Figure 28: Factors influencing the likelihood of new entrants in the pharmaceuticals market in the United States, 2022
Figure 29: Factors influencing the threat of substitutes in the pharmaceuticals market in the United States, 2022
Figure 30: Drivers of degree of rivalry in the pharmaceuticals market in the United States, 2022
